Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer. Lee IH, Lee SJ, Kang B, Lee J, et al. Breast Cancer Res Treat 2024 Jan 27. doi: 10.1007/s10549-023-07198.

Read + Share

Amedeo Smart

Independent Medical Education

Lee IH, Lee SJ, Kang B, Lee J, et al. Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer. Breast Cancer Res Treat 2024 Jan 27. doi: 10.1007/s10549-023-07198.
PMID: 38279017